Cocrystal Pharma (COCP) Extends Drug Discovery Collaboration with HitGen and InterX

Go back to Cocrystal Pharma (COCP) Extends Drug Discovery Collaboration with HitGen and InterX

Cocrystal Pharma Extends Drug Discovery Collaboration with HitGen and InterX

March 10, 2021 8:00 AM EST

BOTHELL, Wash, March 10, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (Cocrystal or the Company), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces an extension of its drug discovery collaboration with HitGen, a biotech company with an innovative DNA Encoded Library technology, and InterX Inc., a... More